Research

Publications:

1.                  Loomba R and Marshall JP, St. Luke's Hospital, St. Louis. Mesocaval shunt graft migration through the bowel wall and passing through the ileostomy. Poster presentation at ACG meeting at Seattle, Oct. 2002.

 

2.                  Loomba R, Brunt EM, Luxon BA, Bacon BR, and Neushwander-Tetri BA. Long-term outcome of patients with autoimmune hepatitis with high or low dose prednisone as initial therapy is equal. Oral presentation in DDW, May 2002. Gastroenterology (abstr) 2002; 122:A-628: 109

 

3.                  Feld J, Gladwin M, Kleiner D, Loomba R, Liang TJ, Hoofnagle JH and Heller T. Liver Diseases Branch, NIDDK NIH. Liver disease in sickle cell anemia. Poster presentation at AASLD, 2005.

 

4.                  Borg B, Neumann A, Ghany M, Heller T, Kleiner D, Loomba R, Liang TJ and Hoofnagle JH. Liver Diseases Branch, NIDDK, NIH. Trial of low dose peginterferon alfa-2a and ribavirin for patients with chronic hepatitis C infected with genotype 2 or 3. Poster presentation at AASLD, 2005.

 

5.                  Lutchman G, Neumann A, Ghany M, Heller T, Loomba R, Liang TJ and Hoofnagle JH. Liver Diseases Branch, NIDDK, NIH. Early viral kinetics in patients with chronic hepatitis C and end stage renal disease during therapy with Peginterferon a-2a. Poster presentation at AASLD, 2005.

 

6.                  Ghany M, Lutchman G, Kleiner D, Borg B, Heller T, Loomba R, Liang TJ, and Hoofnagle JH. Liver Diseases Branch, NIDDK, NIH. Lamivudine and Adefovir versus Adefovir alone for HbeAg-positive chronic hepatitis B. Poster presentation at AASLD, 2005.

 

7.                  Loomba R and Heller T. Liver Diseases Branch, NIDDK, NIH. Prospective study of liver involvement in Turner Syndrome: elevation in liver enzymes and their relation with syndrome specific features. Poster presentation at NIDDK Fellows Retreat, 2005.

 

8.                  Loomba R, Lutchman G, Kleiner D, Heller T, Ghany M, Liang TJ and Hoofnagle JH. Liver Diseases Branch, NIDDK, NIH. Histologic changes in nonalcoholic steatohepatitis in untreated patients: a paired liver biopsy study. Poster presentation in NASH clinical research forum in DDW, 2005.

 

9.                  Loomba R, McBurney R, Lutchman GA, Rehermann B, Herrine SK, Alter H, Liang TJ, Hoofnagle JH and Heller T. Liver Diseases Branch, NIDDK, NIH. Acute hepatitis C: clinical presentation, laboratory findings, and treatment outcomes. Oral presentation at AASLD, 2005.

 

10.              Loomba R, Lutchman GA, Kleiner D, Feld J, Borg B, Ghany M, Heller T, Doo E, Modi A, Liang TJ, and Hoofnagle JH. Liver Diseases Branch, NIDDK, NIH. Metformin for the treatment of nonalcoholic steatohepatitis. Oral presentation at AASLD 2006.

 

11.              Feld JJ, Lutchman GA, Loomba R, Ghany M, Heller T, Liang TJ,  Neumann A, Hoofnagle JH. Liver Diseases Branch, NIDDK, NIH, Bethesda, MD. Should peginterferon be dosed twice weekly? Poster presentation at AASLD meetings 2007.

 

12.              Rotman Y, Borg B, Soza A, Loomba R, Modi AA, Feld JJ, Rivera E, Doo E, Heller T, Ghany MG, Liang TJ, Hoofnagle JH.  Liver Diseases Branch, NIDDK, NIH, Bethesda, MD. Low dose peginterferon alfa-2a and ribavirin for chronic hepatitis C, genotype 2 & 3: viral kinetics, efficacy and safety. Poster presentation at AASL meetings 2007.

 

13.              Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, and Csako G. Liver Diseases Branch, NIDDK, NIH, Bethesda, MD. Pre-emptive lamivudine reduces the risk of chemotherapy-induced HBV-related morbidity and mortality in HBsAg positive cancer patients: A Meta-analysis. Poster presentation at AASLD meetings 2007.

 

14.              Loomba R, Rowley A, Wesley R, Smith K, Liang TJ, Pucino F, and Csako G. Hepatitis B immunoglobulin and lamivudine reduce hepatitis B related morbidity and mortality post-liver transplantation: Meta-analysis. Poster presentation at DDW meetings 2008.

 

15.              Loomba R, Bettencourt R, and Barrett-Connor E. Sex-specific association between alcohol intake, body size and serum aminotransferase levels: The Rancho Bernardo Study. Poster presentation at AASLD meetings 2008.

 

16.              Loomba R, Bettencourt R, Brenner D and Barrett-Connor E. Serum γ-glutamyl transpeptidase independently predicts mortality in older adults: The Rancho Bernardo Study. Poster presentation at DDW meetings 2009.

 

17.              Loomba R, Yang YI, Su J, Brenner DA, Iloeje U, and Chen CJ. Synergistic effect of obesity and alcohol on risk of hepatocellular carcinoma in men: a prospective cohort study. Poster presentation at AASLD meetings 2009.

 

18.              Loomba R, Rao F, Zhang L, Khandrika S, Ziegler M, Brenner DA, and O'Connor DT. Genetic covariance between gamma-glutamyl transpeptidase (GGT) and fatty liver risk factors, as well as the novel effect of b2-adrenergic receptor (ADRB2) genetic variation: A twin study.  Poster presentation at AASLD meetings 2009.

 

19.              Loomba R, Yang YI, Su J, Brenner DA, Barrett-Connor E, and Chen CJ. Synergistic effect of obesity and alcohol on risk of hepatocellular carcinoma: a prospective cohort study. Poster presentation at DDW meetings 2010.

 

20.              Dong M, Bettencourt R, Barrett-Connor E, and Loomba R. Alanine aminotransferase decreases with age: The Rancho Bernardo Study. Oral presentation at DDW 2010.

 

21.              Loomba R, Neuschwander-Tetri BA, Sanyal AJ, Chalasani NC, Kowdley K, McCullough AJ, Diehl AM, Bass NM,  Lavine JE, Brunt EM, Kleiner D, Donithan M, Van Natta M, Tonascia J, Unalp A, Clark JM, and Robuck PR for the NASH CRN. Changes in ALT and vitamin E levels and histological response in patients with NASH treated with vitamin E in the PIVENS trial. Poster presentation at AASLD 2010.

 

22.              Boland B, Bettencourt R, Brenner DA, Barrett-connor E, and Loomba R. Association between serum bilirubin and mortality in older adults: The Rancho Bernardo Study. Poster presentation at DDW 2011.

 

23.              Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, Bass NM. and the NASH Clinical Research Network. Association between family history of diabetes and risk of nonalcoholic steatohepatitis. Poster presentation at DDW 2011.

 

24.              Noureddin M, Vaughn I, Neuschwander-Tetri BA, Sanyal AJ, McCullough AJ, Merriman R, Yates K, Tonascia J, Ünalp-Arida A, Doo E, Kleiner DE, Behling C, and Loomba R and the NASH CRN. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in the elderly. Poster presentation at AASLD 2011.

 

25.              Le TA, Chen J, Changchien C, Peterson M, Kono Y, Patton H, Cohen BL, Brenner DA, Sirlin C and Loomba R for the San Diego NAFLD Research Consortium (SINC). Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial". Poster presentation at DDW 2012.

 

26.              Permutt Z, Le TA, Peterson M, Seki E, Brenner DA, Sirlin C and Loomba R. Correlation between liver histology and novel magnetic resonance imaging in adult patients with nonalcoholic fatty liver disease. Poster presentation at DDW 2012.

 

27.              Tang A, Chen J, Le TA, Changchien C, Hamilton G, Middleton MS, Sirlin CB, and Loomba R. Novel assessment of total liver fat index and liver volume using magnetic resonance imaging in patients with nonalcoholic fatty liver disease. Poster presentation at AASLD 2012.

 

28.              Bambha K, Wilson L, Unalp A, Loomba R, Neuschwander-Tetri B, Brunt EM, and Bass NM. Coffee Consumption in NAFLD Patients with Lower Insulin Resistance is Associated with Lower Risk of Severe Fibrosis. Poster presentation at AASLD 2012.

 

29.              Loomba R, Liu J, Yang HI, Brenner D, and Chen CJ. Synergistic interaction between family history of hepatocellular carcinoma and hepatitis B virus infection in increasing the risk of incident hepatocellular carcinoma. Poster presentation at AASLD 2012.

 

30.              Noureddin M, Le TA, Peterson MR, Middleton MS, Hamilton G, Changchien C, Brenner D, Sirlin CB, and Loomba R. Liver fat quantification using novel magnetic resonance imaging (MRI) technique correlates robustly with MR spectroscopy and histology: A longitudinal study with repeat measures in patients with nonalcoholic fatty liver disease. Poster presentation at AASLD 2012.

 

31.              Liu S, Bettencourt R, Schlang AM, Fehmi SAM, Brenner D, Sirlin CB, Barrett-Connor E, and Loomba R. Novel effect of aging shows decline in fatty liver despite increase in visceral fat: A prospective population-based cohort study. Poster presentation at AASLD 2012.

 

32.              Kohli R, Dodd CN, Loomba R, Fenchel M, Belt PH, Yeh MM, Rosenthal P, Sanyal AJ, and Xanthakos S. High Serum Alpha-1-Antitrypsin Levels are Associated with More Fibrosis in NASH. Poster presentation at AASLD 2012.

 

33.              Lavine JE, Yates KP, Brunt EM, Kleiner DE, Schwimmer JB, Murray KF, Molleston JP, Abrams SH, Rosenthal P, Loomba R, Unalp A, and Tonascia J. The natural history of nonalcoholic fatty liver disease in children and adolescents assessed in placebo recipients in the TONIC trial. Poster presentation at AASLD 2012.

 

34.              Tang A, Szeverenyi NM, Cunha GM, Lam J, Loomba R, Ehman RL, MD Sirlin C. Liver MR Elastography: A Primer for Radiologists. Education Exhibits (Abstract ID 12022950). RSNA Chicago November 2012. Awarded Magna Cum Laude Award.

 

35.              Loomba R, Lam J, Wolfson T, Ang B, Bhatt A, Peterson MR, Brenner DA, and Sirlin C. Magnetic Resonance Elastography Accurately Predicts Advanced Fibrosis in NAFLD: A Pilot Study with Paired-Liver Biopsy. Poster presentation at DDW 2013.

 

36.              Vuppalanchi R, Deppe RB, Yates KP, Comerford M, Masuoka HC, Tetri BA, Loomba R, Brunt E, Kleiner DE, Tonascia J, and Chalasani NP. Changes in Serum Cytokeratin 18 Levels Significantly Predict Changes in Liver Histology in Adults With Nonalcoholic Steatohepatitis: Results from the Pivens Trial. Poster presentation at DDW 2013.

 

37.              Lavine JE, Chalasani NP, Guo X, Kwon S, Schwimmer J, Molleston JP, Loomba R, Brunt EM, Chen YD, Goodarzi MO, Taylor KD, Yates KP, Unalp A, and Rotter JI. Novel Genetic Loci Associated With Steatohepatitis and Fibrosis in Hispanic Boys With Nonalcoholic Fatty Liver Disease. Poster presentation at DDW 2013.

 

38.              Doycheva I, Noureddin M, Patel NS, Peterson MR, Brenner DA, Sirlin C, and Loomba R. Effect of Weight Loss on Novel MRI Quantitative Changes in Liver and Pancreatic Fat in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease. Poster presentation at DDW 2013.

 

39.              Desai A, Tang A, Wolfson T, Peterson M, Clark L, Loomba R, Middleton M, Sirlin

C. Accuracy of magnetic resonance imaging (MRI) estimated proton density fat fraction (PDFF) thresholds for diagnosis of histology determined steatosis grades in adults with non-alcoholic fatty liver disease. ARRS Washington DC 2013.

 

40.              Joshi K, Ang B, Gish R, Loomba R, Kuo A, Patton H, Kono Y, and UCSD Medicine. Hepatocellular Carcinoma Surveillance: An Inquiry Into Current Practices. Poster presentation at ILCA 2013.

 

41.              Samala N, May KP, Kleiner DE, and Loomba R. Normal Weight Nonalcoholic Steatohepatitis (NASH). Poster presentation at AASLD 2013.

 

42.              Loomba R, Alturki A, Han A, Lam J, Ang B, Bhatt A, Hooker J, Shah A, Zand K, Middleton MS, Wolfson T, O'Brien WD, Sirlin CB, and Andre MP. Novel quantification of liver fat by ultrasound backscatter technique & its correlation with MRI-estimated proton density fat fraction in NAFLD vs healthy controls. Poster presentation at AASLD 2013.

 

43.              Patel N, Peterson MR, Lin GY, Bettencourt R, Sirlin CB, and Loomba R. MRI-estimated pancreatic fat is associated with insulin resistance and is greater in patients with non-alcoholic fatty liver disease than healthy controls. Poster presentation at AASLD 2013.

 

44.              Heba E, Desai A, Wolfson T, Chavez T, Lam JC, Hooker J, Clark LG, Loomba R, Gamst A, Sirlin CB, Middleton MS. Correlation Between MRI- and MRS-estimated Proton Density Fat Fraction (PDFF) in 506 Adult Subjects with Non-alcoholic Fatty Liver Disease (NAFLD). (RSNA Abstract ID # 13020771) Poster presentation at RSNA, Chicago, 2013.

 

45.              Alturki AT, Han A, Lam J, Hooker JC, Shah A, Zand KA, Middleton MS, O'Brien WD, Loomba R, Sirlin CB.  Correlation of Quantitative Ultrasound Backscatter with 3T MRI-estimated Proton Density Fat Fraction (PDFF) for Assessment of Hepatic Steatosis. (RSNA Abstract ID # 13020530) Scientific Formal Paper presentation at RSNA, Chicago, 2013.

 

46.              Loomba R, Wolfsen T, Haufe W, Hooker J, Szeverneyi N, Ang B, Peterson M, Valasak M, Lin G, Gamst A, Brenner DA, Sirlin CB. Novel 3-dimensional magnetic resonance elastography accurately diagnoses nonalcoholic steatohepatitis and advanced fibrosis in patients with biopsy- proven nonalcoholic fatty liver disease: A prospective cohort study. Oral presentation at EASL, London, 2014.

 

47.              Kim WR, Berg T, Asselah T, Flisiak R, Fung S, Gordon S, Janssen H, Lampertico P, Lau D, Bornstein J, Schall RA, Dinh P, Yee LJ, Martins EB, Lim SG, Loomba R, Petersen J and Marcellin P. APRI and FIB-4 vs histology in chronic hepatitis B patients in tenofovir disoproxil fumarate trials. Poster presentation at EASL, London, 2014

 

48.              Bazick J, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, Doo E, Lavine JE, and Loomba R for the NASH CRN. Clinical model for predicting NASH or advanced fibrosis in patients with diabetes and NAFLD. Poster presentation at DDW, Chicago, 2014.

 

49.              Singh S, Allen AA, Wang Z, Prokop LJ, Murad MH and Loomba R. Fibrosis Progression in Nonalcoholic Fatty Liver Versus Nonalcoholic Steatohepatitis: A Systematic Review and Meta- Analysis of Paired-Biopsy Studies. Poster presentation at DDW, Chicago, 2014.


 

50.              Chang M, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, Doo E, Lavine JE, and Loomba R for the NASH CRN. Patterns in liver histology among normoglycemic, prediabetic, and diabetic patients with NAFLD. Poster presentation at DDW, Chicago, 2014.

 

51.              Loomba R, Sirlin C, Ang B, Bettencourt R, Jain R,Salotti J, Soaft L, Hooker J, Kono Y, Bhatt A, Hernandez L, Nguyen P, Noureddin M, Haufe W, Hooker C, Yin M, Ehman R, Lin G, Valasek M, Brenner D, Richards L. Novel MRI and MRE in ezetimibe versus placebo for the treatment of nonalcoholic steatohepatitis: Randomized-controlled trial (MOZART Trial). Poster presentation at AASLD 2014.

 

52.              Afdhal N, Urban T, Goodman Z, Patel K, Ge D, Guo X, Jiang Z, Zhao X, Paulson M, Gaggar A, Bornstein J, Subramanian M, McHutchison J, Kleinstein S, Long N, Goldstein D, Loomba R, Thompson A. Genome Wide Association Study (GWAS) identifies a SNP near the MRC2 (mannose receptor C, type 2) gene associated with increased liver collagen content in Caucasian HBC patients. Poster presentation at AASLD 2014.

 

53.              Ray Kim W, Loomba R, Lal P, Schall R, Johnson A, Bornstein J, Subramanian M, McHutchison J, Harrison S, Sanyal A. Serum Lysyl Oxidase Like 2 (sLOXL2) Levels Correlate with Ishak Fibrosis Score and Decrease with Treatment with Tenofovir Disoproxil Fumarate (TDF) in Patients with Chronic Hepatitis B (CHB). Poster presentation at AASLD 2014.

 

54.              Loomba R, Wolfson T, Haufe W, Hooker J, Szeverenyi N, Ang B, Bhatt A, Behling C, Brenner D, Yin M, Ehman R, Sirlin C. Comparison of 2-dimensional and 3-dimensional magnetic resonance elastography (MRE) for diagnosis of advanced fibrosis in patients with biopsy-proven NAFLD: A prospective study. Poster presentation at AASLD 2014.

 

55.              Lominadze Z, Harrison S, Charlton M, Loomba R, Neuschwander-Tetri B, Caldwell S, Kowdley K, Rinella M. Survey of Diagnostic and Treatment Patterns of NAFLD and NASH in the United States: Real Life Practices Differ from Published Guidelines. Poster presentation at AASLD 2014.

 

56.              Vodkin I, Valasek M, Bettencourt R, Cachay E, Loomba R. Clinical and Histologic Differences Between HIV-associated NAFLD and Primary NAFLD: A Case-control Study. Poster presentation at AASLD 2014.

 

57.              Lin S, Heba E, Wolfson T, Ang B, Gamst A, Han Aiguo, Erdman J, O'Brien W, Andre M, Sirlin C, Loomba R. Diagnosis and Quantification of Fatty Liver with Quantitative Ultrasound using MRI-Derived Proton Density Fat Fraction as Reference in Patients with and without NAFLD. Poster presentation at AASLD 2014.

 

58.              Jacobs K, Brouha S, Bettencourt R, Sirlin C, Loomba R. Visceral Adiposity but not Hepatic Steatosis is Associated with Coronary Artery Calcification: a Prospective Cohort Study. Poster presentation at AASLD 2014.

 

59.              Desai A, Bettencourt R, Loomba R. Variation in Liver Disease Related Mortality in the United States. Poster presentation at AASLD 2014.

 

60.              Loomba R, Schork N, Chen C, Bettencourt R, Bhatt A, Ang B, Nguyen P, Hernandez H, Richards L, Salotti J, Lin S, Seki E, Nelson K, Sirlin C, and Brenner D for Genetics of NAFLD in twins consortium. Heritability of Hepatic Fibrosis and Steatosis: a Prospective Twin Study.  Poster presentation at DDW 2015.

 

61.              Loomba R and Chalasani N. The Hierarchical Model of NAFLD: Prognostic Significance of Histologic Features in NASH. Poster presentation at DDW 2015.


 

62.              Singh S, Khera R, Allen A, Bongiorno C, Murad M, Chandar A, Singal A, Atkinson S, Thursz, shahand Loomba R. Comparative Effectiveness of Pharmacologic treatments for Non-Alcoholic Steatohepatitis: A systematic Review and Network Meta-Analysis. Poster Presentation at DDW 2015.

 

63.              Lin S, Ang B, Hernandez C, Bettencourt R, Jain R, Salotti J, Richards L, Kono Y, Bhatt A, Linn G, Valasek M, Sirlin C, Brouha S and Loomba R. Novel Cardiovascular Risk Assessment in the Treatment of Nonalcoholic Steatohepatitis: Secondary Analysis of the MOZART randomized Clinical Trial. Poster presentation at DDW 2015.

 

64.              Arulanandan A, Ang B, Bettencourt R, Hooker J, Behling C, Lin G, Valasek M, Ix J, Schnabl B, Sirlin C, and Loomba R. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients with Non Alcoholic Fatty liver Disease Independent of Nonalcoholic Steatohepatitis. Poster presentation at DDW 2015.

 

65.              Cui J, Wolfson T, Ang B, Haufe W, Hernandez C, Verna E, Sirlin C, and Loomba R. Magnetic Resonance Elastography Is Superior to Clinical Prediction Models for Determination of Advanced Fibrosis in Patients with Non- Alcoholic Fatty Liver Disease: A Prospective Study. Poster presentation at DDW 2015.

 

66.              Loomba R, Schork N, Chen C, Bhatt A, Ang B, Nguyen P, Hernandez C, Richards R, Salotti J, Lin S, Nelson K, Sirlin C and Brenner D. Heritability of Hepatic Fibrosis and Hepatic Steatosis, and Their Shared Gene Effects With Metabolic Traits in NAFLD: A Prospective Twin Study. Poster presentation at DDW 2015.

 

67.              Doycheva I, Nguyen P, Cui J, Hofflich H, Bettencourt R, Sirlin C, and Loomba R. Non- Invasive Screening for NAFLD and Advanced Fibrosis in Diabetics in Primary Care Setting by MRI and MRE: A Prospective Pilot Study. Poster presentation at DDW 2015.

 

68.              Verna E, Patel J, Bettencourt R, Kisseleva T, Brenner D, Nguyen P, Hernandez C, and Loomba

R. Novel Association Between Serum Pentraxin-2 Levels and Advanced Fibrosis in Well- Characterized Patients With NAFLD. Poster presentation at DDW 2015.

 

69.              Zarrinpar A, Gupta S, Maurya M, Subramaniam S, and Loomba R. MicroRNAs explain the Discordance of Nonalcoholic Fatty Liver Disease in Monozygotic and Dizygotic Twins: A Prospective Human Twin Study. Poster presentation at DDW 2015.

 

70.              Kim W.R, Berg T, Asselah T, Flisiak R, Fung S, Gordon S, Janssen H, Lampertico P, Lau D, Boornstein J, Schall R, Dinh P, Yee L, Martins E, Lim S, Loomba R, Petersen J, Buti M and Marcellin P. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic in chronic hepatitis B patients. Poster presentation at EASL 2015.

 

71.              Loomba R, and Cortez-Pinto H. Exercise and improvement on NAFLD: Practical recommendation. Editorial at EASL 2015.

 

72.              Cui J, Wolfson T, Ang B, Haufe W, Hernandez C, Verna E, Sirlin C, and Loomba R. Magnetic resonance Elastography is superior to clinical prediction models for determination of advanced fibrosis in patients with Non- Alcoholic Fatty Liver Disease: A Prospective Study. Oral Presentation at EASL 2015.

 

73.              Hameed B, Terrault N, Gill R, Loomba R, Chalasani N, Hoofnagle J, and Van Natta M for the NASH CRN. Separate and combined effects of Obeticholic Acid and Weight Loss in Nonalcoholic Steatohepatitis (NASH). Poster presentation at EASL 2015.


 

74.              Loomba R, Schork N, Chen C-H, Bhatt A, Ang B, Nguyen P, Hernandez C, Richards L, Salotti  J, Lin S, Nelson K, Sirlin C, Brenner D, on behalf of The Genetics of NAFLD in Twin Consortium. Heritability of Hepatic Fibrosis and Hepatic Steatosis and Their Shared Gene Effects with Metabolic Traits in NAFLD: A Prospective Twin Study. Oral presentation at EASL 2015.

 

75.              Kim W, Loomba R, Berg T, Schall R, Lee Y, Dinh P, Flaherty J, Martins E, Jacobson I, Fung S, Gurel S, Buti M, and Marcellin P. HCC Risk Scores: Application of the CU-HCC, GAG-HCC and Page B scores to Chronic Hepatitis B (CHB) Patients Treated with Tenofovir Disproxil Fumerate (TDF). Poster presentation at EASL 2015.

 

76.              Patel J, Bettencourt R, Cui J, Salotti J, Hooker J, Bhatt A, Hernandez C, Nguyen P, Aryafar H, Haufe W, Hooker C, Richards L, Sirlin C, and Loomba R. Non-invasive quantitative decline in liver fat content on MRI and histological respone in nonalcoholic steatohepatitis: A secondary analysis of MOZART trial. Poster Presentation at AASLD 2015.

 

77.              Emson C, Decaris M, Turner S, Beysen C, Li K, Hernandez C, Cui J, Lazaro L, Brenner D, Hellerstein M, and Loomba R. Novel assessment of hepatic collagen turnover rate and its quantitative association with NASH and stage of fibrosis: prospective validation of a non- invasive marker against liver biopsy. Poster presentation at AASLD 2015.

 

78.              Goodman Z, Alaparthi L, Monge F, Patel K, Loomba R, Cadwell S, Lawitz E, Harrison S, Shiffman M, Abdelmalek M, Myers R, Schall R, Subramanian M, McHutchison J, Ratziu V, Sanyal A, and Afdhal N. Correlations between hepatic morphometric collagen contest, histologic fibrosis staging, and serum markers in patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH). Poster presentation at AASLD 2015.

 

79.              Loomba R, Cui J, Betttencourt, Schork N, Chen C, Ikhwan M, Bhatt A, Richards L, Sirlin C, and Brenner D. Risk of cirrhosis in first degree relatives of patients with NAFLD cirrhosis: A prospective study. Poster presentation at AASLD 2015.

 

80.              Harrison S, Goodman Z, Ratziu V, Loomba R, Diehl A, Lawitz E, Hinrichsen H, Bambha K, Abdelmalek M, Myers R, Schall R, Subramanian M, McHutchison J, Afdhal N, and Muir A. Serum lysyl oxidase-like-2 (sLOXL2) levels correlate with fibrosis stage in patients with nonalcoholic steatohepatitis (NASH). Poster presentation at AASLD 2015.

 

81.              Etzion O, Heller T, Han A, Patel R, Koh C, Kleiner D, Mousa O, Loomba R, Bakalov V, and Bondy C. Liver involvement in Turner Syndrome, Is Associated with Extra Hepatic Disease Manifestations. Poster presentation at AASLD 2015.

 

82.              Huntzicker E, Goodman Z, Loomba R, Charlton M, Newstrom D, Yen E, Schall R, Subramanian M, McHutchison J, Karnik S, Myers R, and French D. Hepatic expression of the apoptosis

signal-regulating kinase 1 (ASK1) marker, phosphorylated-P38 (p-P38), correlates with fibrosis stage in patients with NAFLD. Poster presentation at AASLD 2015.

 

83.              Middleton M, Heba E, Hooker C, Neuschwander-Tetri B, Bashir M, Fowler K, Sandrasegaran K, Brunt E, Kleiner D, Doo E, Van Natta M, Tonascia J, Loomba R, and Sirlin C. Cross-sectional and longitudinal agreement of magnetic resonance imaging proton density fat fraction with pathologist grading of hepatic steatosis in adults with nonalcoholic steatohepatitis in a multi- center trial. Poster presentation at AASLD 2015.

 

84.              Abdelmalek M, Kowdley K, Terrault N, Neuschwander-Tetri B, Sanyal S, Loomba R, Yan X, Shringarpure R, Shapiro D, and McCullough A. Effect of Biopsy length on histological response assessment in NASH trials: A secondary analysis of FLINT trial. Poster presentation at AASLD 2015.


 

85.              Loomba R, Sanyal A, Kowdley K, Terrault N, Chalasani N, Abdelmalek M, McCullough A, Yan X, Shringarpure R, Ferguson B, Shapiro D, and Neschwander-Tetri B. Predictors of improvement in NAFLD Activity Score to obeticholic acid: A secondary analysis of FLINT Trial. Poster presentation at AASLD 2015.

 

86.              Lin S, Heba E, Bettencourt R, Sirlin C, and Loomba R. Cross-sectional and longitudinal analysis of advanced MRI-derived measure of liver fat and volume in the treatment of nonalcoholic steatohepatitis: A secondary analysis of RCT. Poster presentation at AASLD 2015.

 

87.              Vuppalanchi R, Siddiqui M, Hallinan E, Abdelmalek M, Neuschwander-Tetri B, Loomba R, Kowdley K, Terrault N, McCullough A, Tonascia J, Brunt E, Kleiner D, Doo E, Chalasani N, and Sanyal A. Transient Elastography is feasible with High Success Rate for Evaluation of Non- Alcoholic Fatty Liver Disease (NAFLD) in Multicenter Setting. Poster presentation at AASLD 2015.

 

88.              Ratziu V, Sanyal A, Loomba R, Cadwell S, Ghalib R, Torres D, McCullough A, Muir A, Myers R, Schall A, Subramanian M. McHutchison J, Bosch J, Harrison S, Abdelmalek M. Characterization of insulin resistance in patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH). Poster presentation at AASLD 2015.

 

89.              Cui J, Heba E, Hernandez C, Haufe W, Hooker J, Sirlin C, and Loomba R. Magnetic Resonance Elastography is Superior to Acoustic Radiation Force Impulse for the Diagnosis of Fibrosis in Patients with Biopsy-Proven NAFLD: A prospective study. Oral presentation at AASLD 2015.

 

90.              Hameed B, Terrault N, Gill R, Loomba R, Chalasani N, Hoofnagle J, and Van Natta M. Clinical and Metabolic Effects Associated With Weight Loss and Obeticholic Acid In Nonalcocholic Steatohepatitis (NASH). Oral presentation at AASLD 2015.

 

91.              Chalasani N, Loomba R, Terrault N, McCullough A, Abdelmalek M, Kowdley K, Neuschwander-Tetri B, Hazra S, Yan X, Shringarpure R, MacConell L, and Sanyal A. Longitudinal changes in FIB-4 and improvement in fibrosis stage with Obeticholic acid: A secondary analysis of FLINT Trial. Oral presentation at AASLD 2015.

 

92.              Jacobs K, Brouha S, Bettencourt R, Barrett-Connor E, Sirlin C, and Loomba R. Association of Nonalcoholic Fatty Liver Disease with Visceral Adiposity but not Coronary Artery Calcification in the  Elderly. Poster Presentation at DDW 2016.

 

93.              Loomba R. 2435163. Comparative Efficacy and Tolerability of Long-Term Pharmacological Interventions for Obesity: A Systematic Review and Network Meta-Analysis. Research Forum at DDW 2016.

 

94.              Loomba R. 2437459. Shared Genetic Effects Between Hepatic Steatosis and Fibrosis: A Prospective Twin Study. Topic Forum at DDW 2016.

 

95.              Loomba R. 2436771. Sitagliptin versus Placebo in the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. Topic Forum at DDW 2016.

 

96.              Loomba R. 2432689. Effect of weight loss on MRE Estimated Stiffness in Patients with Nonalcoholic Fatty Liver Disease. Poster presentation at DDW 2016.

 

97.              Loomba R. 2439775. Serum microRNA Profiling Differentiates NASH and Advanced Fibrosis in Well Characterized Patients with Biopsy-Proven NAFLD. Poster presentation at DDW 2016.


 

98.              Loomba R. 2441091. Evaluation of Effects of Concomitant Medications for NASH and Associated Comorbidities on Histological Improvements with Obeticholic Acid. Poster presentation at DDW 2016.

 

99.              Loomba R. 2434467. Magnetic Resonance Elastography Identifies Fibrosis in Adults with Alpha-1 Antitrypsin Deficiency Liver Disease: A Pilot Prospective Study. Poster Presentation a DDW 2016.

 

100.          Loomba R, Sanyal A.J, Kowdley K.V, Terrault N, Chalasani N.P, Abdelmalek M.F, McCullough A.J, Ferguson B, Lee L, Shringarpure R, Shapiro D, and Neuschwander-Tetri B.A. Predictors of Improvement in NAFLD Activity Score on Placebo: A Secondary Analysis of the FLINT Trial. Oral presentation at EASL 2016.

 

101.          Cui J, Philo L, Nguyen P, Hofflich H, Hernandez C, Bettencourt R, Richards L, Salotti J, Bhatt  A, Hookeer J, Haufe W, Hooker C, Brenner D.A, Sirlin C.B, and Loomba R. Sitagliptin Verses Placebo in the Treatment of Non- Alcoholic Fatty Liver Disease: A Randomized Controlled Trial. Oral presentation at EASL 2016.

 

102.          Shea P.R, Sanyal A, Rockey D.C, Loomba R, Diehl A.M, Kleinstein S.E, Myers R.P, Mani Subramanian G, McHutchison J.G, Abdelmalek M.F, Ratzui V, Afdhal N, Harrison S, Bosch J, and Goldstein D.B. Genome- Wide Association Study of Clinically Significant Portal Hypertension in Patients With Alcoholic Steatohepatitis and Advanced Fibrosis. Poster presentation at EASL 2016.

 

103.          Cui J, Chen C-H, Lo M-T, Schork N, Bettencourt R, Bhatt A, Hooker J, Nelson K.E, Long M.T, Brenner D.A, Sirlin C.B, and Loomba R. Shared Gene Effects Between Hepatic Steatosis and Fibrosis: A Prospective Twin Study. Poster presentation at EASL 2016.

 

104.          Kowdley K.V, Abdelmalek M.F, McCullough A.J, Loomba R, Hameed B, Shringarpure R, Shapiro D, and Sanyal A.J. Evaluation of Effects of concomitant Medications for Non- Alcoholic Steatohepatitis and Associated Comorbidities on Histological Improvements with Obeticholic Acid. Poster presentation at EASL 2016.

 

105.          Shea P.R, Sanyal A, Harrisoon S, Ratziu V, Loomba R, Caldwell S, Diehl A.M, Kleinstein S.E, Myers R.P, Mani Subramanian G, McHutchison J.G, Abdelmalek M.F, Bosch J, Afdhal N, and Goldstein D.B. PNPLA# Variants Confer an Increased Risk of Advanced Fibrosis Due to Non- Alcoholic Steatohepatitis. Poster presentation at EASL 2016.

 

106.          Park C, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, Hooker J, Sy E, Alquiraish M, Loomba R, Valasek M, Rizo E, Richards L, Brenner D, Sirlin C. Magnetic Resonance Elastrography in detection of Fibrosis and Noninvasive measurement of Steatosis in Patients with biopsy-proven nonalcoholic Fatty Liver Disease. Poster presentation at DDW 2016.

 

107.          Singh S, Facciorusso A, Loomba R, Falck-Ytter Y. Magnitude and Kinetics of Decline in Liver Stiffness After Anti-Viral Therapy in Patients with Chronic Hepatitis C: A Systematic Review and Meta-Analysis. Poster presentation at DDW 2016.

 

108.          Samala N, Hallinan E, Kleiner D, Hoofnagle J, Loomba R. Race and Ethnicity in Patients with Nonalcoholic Fatty Liver Disease. Poster presentation at AASLD 2016.

 

109.          Sarkar N, Gururajan A, Li1 B, Jiang Z, Xu R, Djedjos C, Patterson C, Myers R, Goodman Z, Charlton M, Afdhal N, Loomba R. Circulating microRNAs as markers for liver histological lesions in patients with nonalcoholic steatohepatitis. Poster presentation at AASLD 2016.

 

110.          Hameed B, Terrault N, Loomba R, McCullough A, Abdelmalek M, Kowdley K, Tetri B, Sanyal A, Lee L, Ferguson B, Shringarpure R, Shapiro D, Chalasani N. Subgroup Analysis Comparing Obeticholic Acid versus Placebo for Fibrosis Improvement: a Post-hoc Analysis of the FLINT Trial. Poster presentation at AASLD 2016.

 

111.          Patel J, Dulai P, Younossi Z, Sebastiani G, Ekstedt M, Hagström H, Nasr P, Stål P, Kechagias S, Hultcrantz R, Singh S, Loomba R. Risk of Mortality by Fibrosis Stage in NAFLD: A Systematic Review and Meta-Analysis. Poster presentation at AASLD 2016.

 

112.          Ajmera V, Belt P, Wilson L, Gill R, Loomba R, Kleiner D, Tetri B, Terrault N. No Benefit from Modest Alcohol Use in Nonalcoholic Fatty Liver Disease (NAFLD). Poster presentation at AASLD 2016.

 

113.          Llorente-Izquierdo A, Jepsen P, Inamine T, Bluemel S, Wang L, Wang H, Loomba R, Bajaj J, Schubert M, Sikaroodi M, Gillevet P, DePew J, Du X, Sørensen H, Vilstrup H, Nelson K, Brenner A, Fouts D, Schnabl B. Gastric Acid Suppression Promotes Chronic Liver Disease by Inducing Overgrowth of Intestinal Enterococcus. Poster presentation at AASLD 2016.

 

114.          Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt B, Dulai P, Bettencourt R, Highlander S, Jones M, Sirlin C, Schnabl B, Brinkac L, Schork N, Chen C, Brenner D, Biggs W, Yooseph C, Venter C, Nelson K. Novel gut-microbiota based metagenomic signature for the non-invasive detection of advanced fibrosis in nonalcoholic fatty liver disease: A prospective study. Poster presentation at AASLD 2016.

 

115.          Loomba R, Cui J, Bettencourt R, Schork N, Chen C, Ikhwan M, Gonzalez M, Mendler M, Kono Y, Vodkin I, Mekeel K, Halldorson J, Hemming A, Andrews B, Salotti J, Brenner B, Sirlin C, Richards L. Increased risk of cirrhosis in first degree relatives of patients with NAFLD cirrhosis: A prospective study. A poster presentation at AASLD 2016.

 

116.          Sanyal A, Ratziu V, Harrison S, Abdelmalek M, Aithal G, Caballeria J, Francque S, Farrell G, Kowdley K, Craxì A, Simon K, Fischer L, Melchor-Khan L, Vest J, Wiens B, Vig P, Seyedkazemi S, Goodman Z, Wong V, Loomba R, Tacke F, Friedman S, Lefebvre E. Cenicriviroc placebo for the treatment of non-alcoholic steatohepatitis with liver fibrosis: Results from the Year 1 primary analysis of the Phase 2b CENTAUR study. A poster presentation at AASLD 2016.

 

117.          Loomba R, Lawitz E, Mantry P, Jayakumar S, Caldwell S, Arnold H, Diehl A, Djedjos C, Jia C, Myers R,  Subramanian M, McHutchison J, Goodman Z, Afdhal N, Charlton M. GS-4997, an Inhibitor of Apoptosis Signal-Regulating Kinase (ASK1), Alone or in Combination with Simtuzumab for the Treatment of Nonalcoholic Steatohepatitis (NASH): A Randomized, Phase 2 Trial. A poster presentation at AASLD 2016.

 

118.          Turner A, Lickliter J, Stolk J, Bals R, Hamilton J, Christianson D, Given B, Burdon J, Loomba R, Stoller J, Teckman J. RNA interference (RNAi) with ARC-AAT provides deep and prolonged knockdown of alpha-1 antitrypsin levels in healthy volunteers. A poster presentation at AASLD 2016.

 

119.          Diehl A.M., French D, Xu R, Loomba R, Lawitz E, Freilich B, Shiffman M.L., Chalasani N, Hameed B, Caldwell S, Rinella M, Peach M, Huntzicker E, Turner S, Sullivan T, Chen G, Djedjos C.S., Myers R.P., Subramanian G.M., Goodman Z, Sirlin C, Charlton M, Afdhal N.H. Treatment with selonsertib, an inhibitor of apoptosis signal regulating kinase 1, hepatic phospho-p38 expression and markers of hepatocellular apoptosis and necrosis in patients with nonalcoholic steatohepatitis. A poster presentation at EASL 2017.

 

120.          Younossi Z.M., Stepanova M, Goodman Z, Lawitz E, Charlton M, Loomba R, Hunt S. Improvement of hepatic fibrosis in patients with non-alcoholic steatohepatitis treated with selonsertib is associated with improvement of patient-reported outcomes (PROS). A poster presentation at EASL 2017.

 

121.          Loomba R, Gindin Y, Jiang Z, Lawitz E, Djedjos C.S., Caldwell S, Xu R, Gong D, Myers R.P., Subramanian G.M., Goodman Z, Charlton M, Afdhal N.H., A.M. Diehl A.M. Methylation signatures in blood show accelerated epigenetic aging in patients with non-alcoholic steatohepatitis compared to healthy controls. A poster presentation at EASL 2017.

 

122.          Brandman, Boyle M, McPherson S, Van Natta M, Sanyal A, Kowdley K, Tetri B, Chalassani N, Abdelmalek M, Terrault N.A., McCullough A, Bettencourt R, Caussy C. Kleiner D, Behling C, Doo E, Tonascia J, Anstee Q, Loomba R. Comparison of clinical prediction rules for detection of cirrhosis in non-alcoholic fatty liver disease: a multicenter, international, collaborative study- NASH CRN (USA) and Newcastle (UK) Cohort D. A poster presentation at EASL 2017.

 

123.          Sanyal1 A, Charles E.D., Neuschwander-Tetri B, Loomba R, Harrison S, Abdelmalek M, Lawitz E, Halegoua-DeMarzio D, Dong Y, Noviello S, Krishnamoorthy S, Luo Y, Christian R. BMS-986036 (pegylated FGF21) in patients with non-alcoholic steatohepatitis: a phase 2 study. A poster presentation at EASL 2017.

 

124.          Turner A, Stolk J, Bals R, Lickliter J, Hamilton J, Christianson D, Given B, Burdon J, Loomba R, Stoller J, Teckman J. Hepatic targeted RNA interference provides deep and prolonged knockdown of alpha-1 antitrypsin levels in ZZ patients. A poster presentation at EASL 2017.

 

125.          Harrison S.A., Abdelmalek M.F., Trotter J.F., Paredes A.H., Arnold H.L., Kugelmas M, Bashir M.R, Ling L, Rossi S.J., DePaoli A.M., Rinella M.E., Loomba R. NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a Phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients. An oral presentation at EASL 2017.

 

126.          Park C.C., Nguyen P, Hernandez C, Bettencourt R, Ramirez K.S., Fortney L, Hooker J, Sy E., Alquiraish M.H., Valasek M.A., Rizo E, Richards L, Brenner D, Sirlin C, Loomba R. Magnetic resonance elastography vs. transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. An oral presentation at EASL 2017.

 

127.          Middleton M.S., Lawitz E, Jayakumar S, Mantry P, Caldwell S, Diehl A.M., Peach M, Xu R, Chen G, Djedjos C.S., Myers R.P., Subramanian G.M., Goodman Z, Charlton M, Afdhal N.H., Sirlin C, Loomba R. Hepatic proton density fat fraction correlates with histologic measures of steatosis and is responsive to change in those measures in a multi-center nonalcoholic steatohepatitis clinical trial. An oral presentation at EASL 2017.

 

128.          Loomba R, Lawitz E, Ghalib R, Elkhashab M, Caldwell S, Abdelmalek M, Kowdley K, Xu R, Chen G, Djedjos C.S., Myers R.P., Subramanian G.M., Goodman Z, Charlton M, Sirlin C, Middleton M.S. Longitudinal changes in liver stiffness by magnetic resonance elastography (MRE), liver fibrosis, and serum markers of fibrosis in a multi-center clinical trial in nonalcoholic steatohepatitis (NASH). An oral presentation at EASL 2017.

 

129.          Loomba R, Lawitz E, Jayakumar S, Mantry P, Caldwell S, Diehl AM, Peach M, Xu R, Djedjos CS, Natha M, Myers M, Subramanian M, Goodman Z, Charlton M, Afdhal N, Sirlin C, Middleton M. Hepatic Proton Density Fat Fraction Correlates with Histologic Measure of Steatosis and is Responsive To Change in Those Measures in a Multi-Center Nonalcoholic Steatohepatitis Clinical Trial. A poster presentation at DDW 2017.

 

130.          Park C, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, Hooker J, Sy E, Alquiraish M, Valasek M, Rizo E, Richards L, Brenner D, Sirlin C, Loomba R. Magnetic Resonance Elastography VS. Transient Elastography in Detection of Fibrosis and Noninvasive measurement of Steatosis in patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease. A poster presentation at DDW 2017.

 

131.          Singh S, Facciorusso A, Loomba R, Falck-Ytter Y. Magnitude and Kinetics of Decline in Liver Stiffness After Anti-Viral Therapy In Patients With Chronic Hepatitis C: A systematic Review and Meta-Analysis. A poster presentation at DDW 2017.

 

132.          Kemme S, Miles M, Loomba R, Xanthakos S, Kohli R. Reduced Coenzyme Q10 Levels Are Associated with Advanced Fibrosis in Adults With Nonalcoholic Steatohepatitis. A poster presentation at DDW 2017.


 

Editorials

  1. Stinton L*, Loomba R. Dissecting the PNPLA3 association with liver fat and stiffness, and interaction with diet. Aliment Pharmacol Ther. 2014 Apr;39(8):894-5
  2. Loomba R. Serum alanine aminotransferase as a biomarker of treatment response in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2014 Oct;12(10):1731-2
  3. Loomba R. Rationale for conducting randomized trial to examine the efficacy of metformin in improving survival in cirrhosis: Pleiotropic effects hypothesis. Hepatology 2014 Dec;60(6):1818-22
  4. Roh YS, Loomba R, Seki E. The TM6SF2 Variants, Novel Genetic Predictors for Nonalcoholic Steatohepatitis. Gastroenterology 2015 Jan;148(1):252-4
  5. Spengler EKJ*, Loomba R. Gut microbiome, Intestinal permeability, bacterial translocation and NAFLD. In press Cellular and Molecular Gastroenterology and Hepatology 2015
  6. Verna EC, Loomba R. Call to screen for NAFLD and NASH in psoriasis. Aliment Pharmacol Ther. 2015 Mar;41(5):492-3
  7. Loomba R, Cortez-Pinto H. Exercise and improvement of NAFLD: Practical recommendations. J Hepatol. 2015 Jul;63(1):10-2.
  8. Konerman M, Loomba R. Diabetes and its association with hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther. 2015 Jul;42(1):117-8
  9. Loomba R, Chalasani N. The Hierarchical Model of NAFLD: Prognostic Significance of Histologic Features in NASH. Gastroenterology. 2015 Aug;149(2):278-81
  10. Singh S and Loomba R. Obesity in chronic liver diseases - increased infections. Aliment Pharmacol Ther. 2016 Jan;43(2):311-2
  11. Kishore R, Loomba R, Sterling RK. Editorial: A New Spin on Magnetic Resonance Elastography. Am J Gastroenterol. 2016 Jun;111(6):834-7
  12. Konerman MA, Loomba R. Editorial: the burden and aetiology of liver cirrhosis, and the risk of death. Aliment Pharmacol Ther. 2016 Jul;44(2):202-3
  13. Malhi H, Loomba R. Editorial: dark chocolate may improve NAFLD and metabolic syndrome by reducing oxidative stress. Aliment Pharmacol Ther. 2016 Sep;44(5):533-4
  14. Venkatesh SK, Loomba R. Non-invasive estimation of HVPG by combined structural and hemodynamic evaluation of portal hypertension using quantitative magnetic resonance imaging. J Hepatology 2016 [Epub ahead of print]